AIRLINK 189.64 Decreased By ▼ -7.01 (-3.56%)
BOP 10.09 Decreased By ▼ -0.05 (-0.49%)
CNERGY 6.68 Decreased By ▼ -0.01 (-0.15%)
FCCL 34.14 Increased By ▲ 1.12 (3.39%)
FFL 17.09 Increased By ▲ 0.44 (2.64%)
FLYNG 23.83 Increased By ▲ 1.38 (6.15%)
HUBC 126.05 Decreased By ▼ -1.24 (-0.97%)
HUMNL 13.79 Decreased By ▼ -0.11 (-0.79%)
KEL 4.77 Increased By ▲ 0.01 (0.21%)
KOSM 6.58 Increased By ▲ 0.21 (3.3%)
MLCF 43.28 Increased By ▲ 1.06 (2.51%)
OGDC 224.96 Increased By ▲ 11.93 (5.6%)
PACE 7.38 Increased By ▲ 0.37 (5.28%)
PAEL 41.74 Increased By ▲ 0.87 (2.13%)
PIAHCLA 17.19 Increased By ▲ 0.37 (2.2%)
PIBTL 8.41 Increased By ▲ 0.12 (1.45%)
POWER 9.05 Increased By ▲ 0.23 (2.61%)
PPL 193.09 Increased By ▲ 9.52 (5.19%)
PRL 37.34 Decreased By ▼ -0.93 (-2.43%)
PTC 24.02 Decreased By ▼ -0.05 (-0.21%)
SEARL 94.54 Decreased By ▼ -0.57 (-0.6%)
SILK 0.99 Decreased By ▼ -0.01 (-1%)
SSGC 39.93 Decreased By ▼ -0.38 (-0.94%)
SYM 17.77 Decreased By ▼ -0.44 (-2.42%)
TELE 8.66 Decreased By ▼ -0.07 (-0.8%)
TPLP 12.39 Increased By ▲ 0.18 (1.47%)
TRG 62.65 Decreased By ▼ -1.71 (-2.66%)
WAVESAPP 10.28 Decreased By ▼ -0.16 (-1.53%)
WTL 1.75 Decreased By ▼ -0.04 (-2.23%)
YOUW 3.97 Decreased By ▼ -0.03 (-0.75%)
AIRLINK 189.64 Decreased By ▼ -7.01 (-3.56%)
BOP 10.09 Decreased By ▼ -0.05 (-0.49%)
CNERGY 6.68 Decreased By ▼ -0.01 (-0.15%)
FCCL 34.14 Increased By ▲ 1.12 (3.39%)
FFL 17.09 Increased By ▲ 0.44 (2.64%)
FLYNG 23.83 Increased By ▲ 1.38 (6.15%)
HUBC 126.05 Decreased By ▼ -1.24 (-0.97%)
HUMNL 13.79 Decreased By ▼ -0.11 (-0.79%)
KEL 4.77 Increased By ▲ 0.01 (0.21%)
KOSM 6.58 Increased By ▲ 0.21 (3.3%)
MLCF 43.28 Increased By ▲ 1.06 (2.51%)
OGDC 224.96 Increased By ▲ 11.93 (5.6%)
PACE 7.38 Increased By ▲ 0.37 (5.28%)
PAEL 41.74 Increased By ▲ 0.87 (2.13%)
PIAHCLA 17.19 Increased By ▲ 0.37 (2.2%)
PIBTL 8.41 Increased By ▲ 0.12 (1.45%)
POWER 9.05 Increased By ▲ 0.23 (2.61%)
PPL 193.09 Increased By ▲ 9.52 (5.19%)
PRL 37.34 Decreased By ▼ -0.93 (-2.43%)
PTC 24.02 Decreased By ▼ -0.05 (-0.21%)
SEARL 94.54 Decreased By ▼ -0.57 (-0.6%)
SILK 0.99 Decreased By ▼ -0.01 (-1%)
SSGC 39.93 Decreased By ▼ -0.38 (-0.94%)
SYM 17.77 Decreased By ▼ -0.44 (-2.42%)
TELE 8.66 Decreased By ▼ -0.07 (-0.8%)
TPLP 12.39 Increased By ▲ 0.18 (1.47%)
TRG 62.65 Decreased By ▼ -1.71 (-2.66%)
WAVESAPP 10.28 Decreased By ▼ -0.16 (-1.53%)
WTL 1.75 Decreased By ▼ -0.04 (-2.23%)
YOUW 3.97 Decreased By ▼ -0.03 (-0.75%)
BR100 11,814 Increased By 90.4 (0.77%)
BR30 36,234 Increased By 874.6 (2.47%)
KSE100 113,247 Increased By 609 (0.54%)
KSE30 35,712 Increased By 253.6 (0.72%)
Business & Finance

EU regulator approves Moderna vaccine as fears grow over virus variants

  • Vaccinating the European Union's 450 million people could be crucial to ending a pandemic that has killed almost 1.9 million people globally.
  • The final step before it can be rolled out across the European Union is approval by the bloc's executive body.
Published January 6, 2021

AMSTERDAM: Europe's drug regulator gave the green light to Moderna Inc's COVID-19 vaccine on Wednesday, the second shot it has approved, as authorities accelerate inoculation efforts amid fears about more infectious variants of the coronavirus.

Vaccinating the European Union's 450 million people could be crucial to ending a pandemic that has killed almost 1.9 million people globally. The approval comes as countries are racing to contain two variants found in South Africa and Britain that are more transmissible and have driven a surge in infections.

The EU's European Medicines Authority (EMA) said it had given the go-ahead for the use of the Moderna vaccine on people aged over 18 following an assessment of the data on quality, safety and efficacy.

The final step before it can be rolled out across the European Union is approval by the bloc's executive body, the European Commission, which is expected to follow soon.

The decision, coming just over a year since the first outbreak of the virus was identified in China, marks the second regulatory authorisation for Moderna's vaccine after the United States, and further validation of new genetic mRNA technology.

It was about 95% effective at preventing illness in clinical trials that found no serious safety issues.

The Dutch national drugs authority, the CBG, said the Moderna vaccine was expected to be effective against the mutated variant of the coronavirus detected in Britain, but cautioned this had to be confirmed by further research.

The CBG added that the European Commission was expected to give the final stamp of approval to the shot later on Wednesday.

The EU move follows the conditional marketing approval two weeks ago for a vaccine from Pfizer Inc and BioNTech SE , also based on mRNA technology.

The campaign to vaccinate the EU's population has gotten off to an uneven start, with officials in Germany and France frustrated at the slow rate of progress.

Hundreds of thousands of Europeans have received the shot since the rollout began a week ago. By comparison, Britain has administered more than a million of the Pfizer-BioNTech shots in just under a month.

The Netherlands on Wednesday started vaccinations with that vaccine, giving its first injection to a 39-year old care home nurse.

Comments

Comments are closed.